To examine the effect of betaine supplementation on cycling sprint performance. Sixteen recreationally active subjects (7 females and 9 males) completed three sprint tests, each consisting of four 12 sec efforts against a resistance equal to 5.5% of body weight; efforts were separated by 2.5 min of cycling at zero resistance. Test one established baseline; test two and three were preceded by seven days of daily consumption of 591 ml of a carbohydrate-electrolyte beverage as a placebo or a carbohydrate-electrolyte beverage containing 0.42% betaine (approximately 2.5 grams of betaine a day); half the beverage was consumed in the morning and the other half in the afternoon. We used a double blind random order cross-over design; there was a 3 wk washout between trials two and three. Average and maximum peak and mean power were analyzed with one-way repeated measures ANOVA and, where indicated, a Student Newman-Keuls. Compared to baseline, betaine ingestion increased average peak power (6.4%; p < 0.001), maximum peak power (5.7%; p < 0.001), average mean power (5.4%; p = 0.004), and maximum mean power (4.4%; p = 0.004) for all subjects combined. Compared to placebo, betaine ingestion significantly increased average peak power (3.4%; p = 0.026), maximum peak power max (3.8%; p = 0.007), average mean power (3.3%; p = 0.034), and maximum mean power (3.5%; p = 0.011) for all subjects combined. There were no differences between the placebo and baseline trials. One week of betaine ingestion improved cycling sprint power in recreationally active males and females.
1 May 1999 in Medicine & Science in Sports & Exercise
Noninvasive estimation of the maximal lactate steady state in trained cyclists. Med. Sci. Sports Exerc., Vol. 31, No. 5, pp. 742-746, 1999. The purposes of this study were to estimate noninvasively the maximal lactate steady state (MLSS) in trained cyclists on a windload simulator with a velocity based technique and to determine whether the HR at MLSS (HRMLSS) elicited a similar blood lactate concentration (BLC) during field testing. To determine and verify MLSS, 10 male cyclists performed five to seven laboratory trials on separate days, including a O2max test; a 5-km time trial (TT); and two or more 30-min trials at specific percentages of each subject's average 5-km TT speed (AVS5km). Mean ± SD for the following variables were obtained at MLSS: velocity was 90.3 ± 2.7% of the AVS5km, BLC was 5.4 ± 1.6 mM, RPE was 15 ± 2.1, O2 was 80 ± 6.3% of O2max, and HR was 167 ± 9.5 beats·min−1, which was 88 ± 3.8% of the mean maximum HR. Field tests included three laps of an 8-km road circuit at HRMLSS ± 3 beats·min−1 and one lap at maximum sustainable velocity (a road TT). There were no significant differences in BLC, HR, and RPE between the three steady-state road laps and the lab MLSS trial. There was also good agreement between the road and lab MLSS velocity/TT velocity ratios. Our data suggest that 5-km TT cycling velocity, as measured on a windload simulator, may be used to estimate MLSS and the HR at MLSS for training purposes.
Background: The purpose of this study is to ascertain the reliability of two 15-s sprint cycling tests in men and women to estimate the maximum lactate accumulation rate (VLamax). Methods: Eighteen men and twelve women completed two sprint sessions over 1 week. A 10 min warm-up preceded the obtaining of a 3 µL blood lactate (BLC) sample, after which a 15 s sprint was completed; cyclists then rested passively while multiple lactate samples were taken until the levels peaked. Trial differences and reliability across trials were analyzed using a paired-sample t-test, Pearson’s correlation, Intraclass correlation (ICC), and Bland–Altman analysis with α = 0.05 for all tests; data are reported as mean ± sd. Results: Power (W) was similar across trials (773.0 ± 143.5 vs. 758.2 ± 127.4; p = 0.333) and the coefficient of variation (CV) of 4.7%. VLamax (mM·L−1·s−1) was similar (0.673 ± 0.024 vs. 0.635 ± 0.237; p = 0.280), but only moderately reliable across trials with CV, ICC, and R values of 18.6%, 0.661, and 0.67, respectively. Pre-BLC and peak BLC CV were 45.6 and 23.3%, respectively. Conclusions: A 15 s VLamax cycling sprint is moderately reliable, possibly affected both by the lactate measurement and other variables used in the calculation. More research may offer ways to improve reliability.
Running enjoys worldwide popularity across age groups and sexes. Because of this, it serves as an excellent benchmark to compare male and female performance across the lifespan with respect to developmental progression, peak athletic performance, and age-related regression. The purpose of this review is to examine and discuss how sex and aging affect running performance in sprints, middle-distance running, and long-distance running. Based on the scientific literature and running world records from age 5–99, male running performance exceeds that of females across the lifespan, with the greatest divide beginning at puberty, which remains through old age. However, there appear to be few differences in the rate of progression in youth and the age of peak performance, but it is unclear whether the rate of decline, beginning in middle age, differs by sex and sport for record performances. Future analyses should examine changes in all running performances across the lifespan.
Background: The purpose of this study was to ascertain the reliability of two 15-sec sprint cycling tests in men and women to estimate the maximum rate of glycolysis or lactate production (VLa-Max). Methods: Eighteen men and twelve women completed two sprint sessions over 1-week. A 10-min warm-up preceded a 3 µl blood lactate (BLC) sample, after which a 15-sec sprint was completed; cyclists then rested passively while multiple lactate samples were taken until levels peaked. VLaMax was calculated as (Peak BLC – Pre BLC) * (15-sec – Talac)-1. Trial differences and reliability across trials were analyzed using a paired-sample t-test, Pearson correlation, ICC, and Bland-Altman analysis with α=0.05 for all tests; data are reported as mean ± sd. Results: Power (W) was similar across trails (773.0 ±143.5 vs. 758.2 ± 127.4; p = 0.333) and coefficient of varia-tion (CV) of 4.7%. VLaMax was similar (0.673 ± 0.024 vs 0.635 ± 0.237; p = 0.280), but only moder-ately reliably across trials with a CV, ICC, and R value of 18.6%, 0.661, and 0.67, respectively. Conclusions: A 15-sec VLaMax cycling sprint is moderately reliable being affected both by the lac-tate measurement and other variables used in the calculation. More research may offer ways to improve reliability.
1 May 2005 in Medicine & Science in Sports & Exercise